Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Current Liabilities (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Total Current Liabilities for 16 consecutive years, with $147.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 21.94% year-over-year to $147.2 million, compared with a TTM value of $147.2 million through Dec 2025, up 21.94%, and an annual FY2025 reading of $147.2 million, up 21.94% over the prior year.
  • Total Current Liabilities was $147.2 million for Q4 2025 at Catalyst Pharmaceuticals, up from $128.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $147.2 million in Q4 2025 and bottomed at $14.4 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $68.4 million, with a median of $57.7 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities decreased 20.16% in 2021, then surged 147.23% in 2023.
  • Year by year, Total Current Liabilities stood at $27.1 million in 2021, then surged by 112.79% to $57.6 million in 2022, then surged by 32.08% to $76.1 million in 2023, then soared by 58.66% to $120.7 million in 2024, then rose by 21.94% to $147.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for CPRX at $147.2 million in Q4 2025, $128.7 million in Q3 2025, and $113.0 million in Q2 2025.